About Maxzimaa Pharmaceuticals Private Limited
Data last updated:
Maxzimaa Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 30 December 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24100DL2014PTC274793. Its GSTIN is 09AAJCM5629D1ZC (Uttar Pradesh).
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹25 Lakh. It is led by directors including Sucheta Dhawan and Dhiraj Joshi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 403 Amber Tower 4th Floor Azadpur Commercial Complex, New Delhi, Delhi, India – 110033.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.4 Cr. For the same year it recorded a net profit of ₹1.98 Lakh (net margin 0.6%) and EBITDA of ₹11.38 Lakh (EBITDA margin 3.3%). Revenue has declined at a compounded annual rate (CAGR) of 4% over three years and 4% over five years.
The company has about 57 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹45 Lakh on record. Court records list 1 case involving the company, including 1 filed by the company.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website maxzimaa.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address403 Amber Tower 4th Floor Azadpur Commercial Complex, New Delhi, Delhi, India – 110033
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Maxzimaa Pharmaceuticals Private Limited
The main business activity of Maxzimaa Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Maxzimaa Pharmaceuticals Private Limited FY 2025 filings available
Maxzimaa Pharmaceuticals Private Limited reported revenue of ₹3.4 Cr for FY 2025.
Compounded Annual Growth Rate (CAGR) of Maxzimaa Pharmaceuticals Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 4% over five years. EBITDA rose 32% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Maxzimaa Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹11.38 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹1.98 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Maxzimaa Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.3% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.6% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Maxzimaa Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals has 4 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sucheta Dhawan Also directs: Maxzima Medicare Private Limited, Fortem Security Private Limited | Director | 20 Jan 2015 | 11 Years 9 Months | Current |
| Dhiraj Joshi Also directs: Maanka Healthcare Product LLP, Nuri Sciences Private Limited | Director | 20 Jan 2015 | 11 Years 9 Months | Current |
| Lovpreet Moti | Director | 20 Jan 2015 | 11 Years 9 Months | Current |
| Rachana Khatri | Director | 18 Oct 2018 | 8 Years 0 Months | Current |
Peer Comparison of Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Rishabh Pharmaceuticals Private Limited | ₹3.4 Cr (FY 2024) | •••• | •••• | 23.0% | •••• | Indore, Madhya Pradesh, India |
| Sara Remedies Limited | ₹3.4 Cr (FY 2025) | •••• | •••• | 27.0% | •••• | Chandigarh, India |
| Tyscon Pharmaceuticals Private Limited | ₹3.4 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Zirakpur, Punjab, India |
| Astha Laboratories Private Limited | ₹3.4 Cr (FY 2019) | •••• | •••• | -10.0% | •••• | Hyderabad, Telangana, India |
| JVS Healthcare Private Limited | ₹3.4 Cr (FY 2025) | •••• | •••• | 398.0% | •••• | Civil Lines, Delhi, India |
| Maxzimaa Pharmaceuticals Private Limited this company | ₹3.4 Cr (FY 2025) | •••• | •••• | •••• | New Delhi, Delhi, India | |
| Centenary Pharmaceuticals Private Limited | ₹3.4 Cr (FY 2025) | •••• | •••• | 49.0% | •••• | Pune, Maharashtra, India |
| Saach Pharmaceuticals Private Limited | ₹3.39 Cr (FY 2024) | •••• | •••• | 17.0% | •••• | Manimajra, Chandigarh, India |
| JC Lifecare Private Limited | ₹3.38 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | New Delhi, Delhi, India |
| Bio Trans Pharmaceuticals Private Limited | ₹3.37 Cr (FY 2024) | •••• | •••• | -8.0% | •••• | Athipattu, Tamil Nadu, India |
| Protota Pharmaceuticals Private Limited | ₹3.37 Cr (FY 2024) | •••• | •••• | -18.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Maxzimaa Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals Private Limited is audited by MANOJ K. GARG & COMPANY for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| MANOJ K. GARG & COMPANY | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Maxzimaa Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Maxzimaa Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2025 | Others | ₹45 Lakh | Open |
Total charge records: 1 View all charges
Legal Cases of Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals Private Limited has 1 court case on record: 1 filed by Maxzimaa Pharmaceuticals. All case is disposed. Status as checked on 21 Sep 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| NCLAT | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLAT, New Delhi | Company appeal | Filed by the company against individuals | Disposed |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals Private Limited has a workforce of 57 employees as of Mar 23, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals Private Limited has 7 board changes on record since 2015: 4 appointments and 3 cessations. The latest: Rachana Khatri ceased to be Additional Director on 19 Nov 2018.
Credit Ratings, Litigation & Regulatory Alerts for Maxzimaa Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Maxzimaa Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Maxzimaa Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAJCM5629D1ZC | Uttar Pradesh | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Maxzimaa Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Maxzimaa Pharmaceuticals Private Limited
Maxzimaa Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 30 December 2014 (12+ years old) and is registered under CIN U24100DL2014PTC274793.
Maxzimaa Pharmaceuticals reported revenue of ₹3.4 Cr for FY 2025.
Maxzimaa Pharmaceuticals has 4 current directors:
- Sucheta Dhawan - Director
- Dhiraj Joshi - Director
- Lovpreet Moti - Director
- Rachana Khatri - Director
Maxzimaa Pharmaceuticals reported a net profit of ₹1.98 Lakh (net margin 0.6%) and EBITDA of ₹11.38 Lakh (EBITDA margin 3.3%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Maxzimaa Pharmaceuticals is 4% over three years and -4% over five years. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Maxzimaa Pharmaceuticals is 09AAJCM5629D1ZC, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Maxzimaa Pharmaceuticals is U24100DL2014PTC274793. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Maxzimaa Pharmaceuticals has 1 court case on record: 1 filed by the company.
Maxzimaa Pharmaceuticals was incorporated on 30 December 2014, making it 12+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Maxzimaa Pharmaceuticals by revenue are Rishabh Pharmaceuticals Private Limited, Sara Remedies Limited, Tyscon Pharmaceuticals Private Limited, Astha Laboratories Private Limited, JVS Healthcare Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Rachana Khatri ceased to be Additional Director on 19 Nov 2018. Rachana Khatri was appointed as Director on 18 Oct 2018. Dhiraj Joshi was appointed as Director on 20 Jan 2015. Maxzimaa Pharmaceuticals has 7 board changes on record in total.